U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. FDA-HESI Public Workshop: Preclinical and Translational Safety Assessment of CD3 Bispecifics - 10/01/2018
  1. News & Events for Human Drugs

Public | In Person

Event Title
FDA-HESI Public Workshop: Preclinical and Translational Safety Assessment of CD3 Bispecifics
October 1 - 2, 2018

Date:
October 1 - 2, 2018
Website:
https://collaboration.fda.gov/fdahesi2018

Co-sponsored by the:
U.S. Food & Drug Administration (FDA) and
the Health and Environmental Sciences Institute (HESI)
 

Twitter: #OncCD3biSpec

Date: Oct 1-2, 2018

Time: 8:00 am to 5:00 pm

Location:FDA White Oak Campus, Building 31, Room 1503A - Great Room, 10903 New Hampshire Avenue, Silver Spring, MD 20993.  FDA Campus Information, (e.g., local airports, directions, and local hotels)
 
Registration:
For in-person or webcast participation in this public workshop, please register at the following link: http://hesiglobal.org/event/fda-cder-hesi-workshop-on-preclinical-and-translational-safety-assessment-of-cd3-bispecific/ 
 

Background:
FDA and HESI intend to leverage their combined strengths for the joint development of a workshop that convenes subject matter experts involved in the preclinical and translational development of CD3 bispecific therapies.
 
Workshop Objectives:
The goal of this workshop is to discuss the preclinical and translational safety assessment of CD3 bispecific therapies. The workshop will focus on eight topics, followed by an in-depth discussion:

  • CD3 bispecifics and their effect on T-cell biology,
  • Target (tumor antigen) expression and liability assessment,
  • Relevance of molecular design and bioactivity to toxicity assessment and potential,
  • In-vivo pharmacology and toxicology,
  • In-vitro assays to assess cytokine release,
  • First-In-Humans (FIH) dose selection,
  • Clinical Experience
  • Translation of nonclinical findings to the clinic.

Webcast Information:
FDA will provide a free-of-charge, live webcast of this workshop which will be accessible at this link: https://collaboration.fda.gov/fdahesi2018.
This workshop will not be recorded; therefore, an archived webcast will be unavailable after the meeting.
 

Meeting Information: 

Contacts:
 
FDA/CDER

Health and Environmental Sciences Institute (HESI)

 

Back to Top